Clinical trial NCT03569644: Quality of Life in Patients With Auto-inflammatory Diseases
Official title: Creation of a Tool to Assess Quality of Life in Patient With Auto-inflammatory Diseases
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Hereditary Autoinflammatory Diseases
Lead sponsor: Assistance Publique - Hôpitaux de Paris
Sponsor class: OTHER
First posted: 2018-06-26
Enrollment: 48
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: The study is based on interviews that will be recorded in digital audio and then transcribed literally. The consultation for this research is 45 to 90 minutes long. This prolongs their presence in consultation with the doctor. For this reason, the study was classified as Interventional according to French regulations
Primary purpose: OTHER

Brief summary: This qualitative interview-based study aim to build a tool to assess quality of life in patients (adults or children) suffering from 6 autoinflammatory diseases (FMF, TRAPS, CAPS, MKD, Still and PFAPA).

Detailed description: Recent understanding of the physiopathological mechanisms that underpin autoinflammatory diseases (AIDs) allowed a revolution in the therapeutic management of these patients, particularly through the use of biotherapies. However new treatments need to be evaluated by valid tools. AIDAI score created and validated by our team evaluates activity of 4 autoinflammatory diseases. One of the important components, not explored by the scores currently available, is the impact of these treatments on quality of life (QoL) of patients. The existing quality of life scales are not adapted to these recurrent chronic pathologies. Throught a qualitative study based on interviews of patients and/ or parents, the investigators aim to build a tool to evaluate QoL in patients suffering from 6 aAIDs :familial Mediterranean fever (FMF), mevalonate kinase deficiency (MKD), tumour necrosis factor receptor-associated periodic syndrome (TRAPS), cryopyrin-associated periodic syndromes (CAPS), Still's disease and PFAPA syndrome.

Eligibility criteria: Inclusion Criteria:

* Any patient (child and adult) with one of the 6 AIDs (FMF, TRAPS, MKD or CAPS, PFAPA or Still's disease) regardless of the activity of the disease. The diagnosis will have been made by the referring physician according to criteria specific to each AIDs
* Volunteer to participate in the study
* With at least one parent present at the consultation if it is a child under 18 years old
* For minors, agreement of the parents or their legal representative or one of the present parents
* Information for children as far as their age and condition allow
* Affiliation to a national health insurance.

Exclusion Criteria:

* patient or relative (according to age)refuse to participate.
* Bad understanding of French.
* Other chronic inflammatory pathology associated (example: Crohn's, SPA, uveitis, psoriasis ...)

Primary outcomes:
measure: Qualitative evaluation of quality of life by interviews of patients and/or parents
timeFrame: 45 to 90 min
Secondary outcomes:
Other outcomes:
Locations:
city: Le Chesnay
country: France
facility: CH André Mignot
city: Le Kremlin Bicêtre
country: France
facility: Dr Maryam PIRAM
city: Paris
country: France
facility: TENON
Study officials:
References: